Date:	2021/1	.2/22		
Your Name:	:	Yi Zhang		
Manuscript	:Title:	The co-mutation	of EGFR and tumor-related genes leads to a worse prognosis and a higher	level of
tumor muta	ational b	urden in Chinese r	non-small cell lung cancer patients	
Manuscript	numbe	r (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ _None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	 None			
	testimony				
7	Support for attending meetings and/or travel	 None			
8	Patents planned, issued or	⊻ _None			
	pending				
9	Participation on a Data	∠ _None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ _None			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid	4 N			
11	Stock or stock options	v _None			
12		4			
12	Receipt of equipment,	v _None			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	✓ None			
	financial interests				
Ple	ase summarize the above co	Please summarize the above conflict of interest in the following box:			

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Date:	2021/1	2/22				
Your Name:	:	Shirong Li				
Manuscript	:Title:	The co-mutation of EGFR a	and tumor-related genes	leads to a worse prognosis	s and a higher lev	vel of
tumor muta	ational b	urden in Chinese non-small	II cell lung cancer patients		_	
Manuscript	number	(if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _✓_None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	_ None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ _None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	 None			
	testimony				
7	Support for attending meetings and/or travel	 None			
8	Patents planned, issued or	⊻ _None			
	pending				
9	Participation on a Data	∠ _None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ _None			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid	4 N			
11	Stock or stock options	v _None			
12		4			
12	Receipt of equipment,	v _None			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	✓ None			
	financial interests				
Ple	ase summarize the above co	Please summarize the above conflict of interest in the following box:			

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Date:	2021/12/22	
Your Name:	:Zhi Lyu	
Manuscript	Title:The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher	level of
tumor muta	ational burden in Chinese non-small cell lung cancer patients	
Manuscript	number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _✓_None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
2	Cuanta au aputuanta fuana	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	✓ None	
	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or	 _None	
	pending		
0	Participation on a Bata	4.11	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	✓ None	
10	in other board, society,	<u></u>	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12		4	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021/1	12/22			
Your Name:	:	Jinghuang Cai			
Manuscript	:Title:	The co-mutation o	of EGFR and tumor-related genes leads to a worse prognosis and a higher level of		
tumor muta	ational k	ourden in Chinese no	on-small cell lung cancer patients		
Manuscript number (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	 None	
7	Support for attending meetings and/or travel	 None	
8	Patents planned, issued or pending	⊻ _None	
9	Participation on a Data Safety Monitoring Board or	∠ _None	
	Advisory Board		
10	Leadership or fiduciary role	_ _None	
	in other board, society, committee or advocacy		
11	group, paid or unpaid	4 N	
11	Stock or stock options	v _None	
12		4	
12	Receipt of equipment,	v _None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
Ple	ase summarize the above co	onflict of interest in the	following box:

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Date:	021/12/22				
Your Name:	Naishan Zheng				
Manuscript	tle:The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level	of			
umor mutational burden in Chinese non-small cell lung cancer patients					
Manuscript number (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	 None	
7	Support for attending meetings and/or travel	 None	
8	Patents planned, issued or pending	⊻ _None	
9	Participation on a Data Safety Monitoring Board or	∠ _None	
	Advisory Board		
10	Leadership or fiduciary role	_ _None	
	in other board, society, committee or advocacy		
11	group, paid or unpaid	4 N	
11	Stock or stock options	v _None	
12		4	
12	Receipt of equipment,	v _None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
Ple	ase summarize the above co	onflict of interest in the	following box:

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Date:	2021/1	.2/22		
Your Name:		Yanping Li		
Manuscript	Title:	The co-mutation	of EGFR and tumor-related genes leads to a worse prognosis and a	higher level of
tumor muta	ational b	urden in Chinese n	non-small cell lung cancer patients	
Manuscript	numbe	r (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	 None	
7	Support for attending meetings and/or travel	 None	
8	Patents planned, issued or pending	 None	
9	Participation on a Data Safety Monitoring Board or	∠ _None	
	Advisory Board		
10	Leadership or fiduciary role	_ _None	
	in other board, society, committee or advocacy		
11	group, paid or unpaid	4 N	
11	Stock or stock options	v _None	
12		4	
12	Receipt of equipment,	v _None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
Ple	ase summarize the above co	onflict of interest in the	following box:

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Date:	2021/12	2/22			
Your Name:	:	Tianwen Xu			
Manuscript	:Title:	The co-mutation	of EGFR and tumor-related genes leads to a worse prognosis and a higher level of		
umor mutational burden in Chinese non-small cell lung cancer patients					
Aanuscript number (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ _None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	 None		
	testimony			
7	Support for attending meetings and/or travel	 None		
8	Patents planned, issued or	⊻ _None		
	pending			
9	Participation on a Data	⊻ _None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	 _None		
	in other board, society,			
	committee or advocacy			
4.4	group, paid or unpaid	4 21		
11	Stock or stock options	None		
		4		
12	Receipt of equipment,	<u>v_</u> None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	✓ None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Date:202	21/12/22	
Your Name:	Huiqing Zeng	
Manuscript Title	e:The co-mutation o	f EGFR and tumor-related genes leads to a worse prognosis and a higher level of
tumor mutation	nal burden in Chinese no	on-small cell lung cancer patients
Manuscript nun	nber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial None	Thanks to Shanghai Tongshu Biotechnology Co., Ltd. for its sequencing service
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ _None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	 None		
	testimony			
7	Support for attending meetings and/or travel	 None		
8	Patents planned, issued or	⊻ _None		
	pending			
9	Participation on a Data	⊻ _None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	 _None		
	in other board, society,			
	committee or advocacy			
4.4	group, paid or unpaid	4 21		
11	Stock or stock options	None		
		4		
12	Receipt of equipment,	<u>v_</u> None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	✓ None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			

The author reports the technical support from Shanghai Tongshu Biotechnology Co., Ltd.